Las Vegas Lecture 1.Pub

Total Page:16

File Type:pdf, Size:1020Kb

Las Vegas Lecture 1.Pub Hildenbrand G pg. 1 Practice of Gerson’s diet therapy in neoplastic diseases: A tissue-centric nutritional immunotherapy that anticipated Matzinger’s Danger Model with its tissue-based effector class control Gar Hildenbrand Dir Epidemiology - Gerson Research Organization Dir Research – Centro Hospitalario Internacional del Pacifico SA Lecture and PowerPoint presentation to the American Academy of Anti-Aging Medicine Fellowship in Integrative Cancer Therapy: Module II June 25, 2011 Las Vegas, Nevada Fellowship Dir: Mark Rosenberg, M.D. Hildenbrand G pg. 2 Gerson Research Organization 7807 Artesian Rd San Diego CA 92127 http://www.gerson-research.org garhildenbrand.com email: [email protected] Hildenbrand G pg. 3 Practice of Gerson’s diet therapy in neoplastic diseases: A tissue-centric nutritional immunotherapy that anticipated Matzinger’s Danger Model with its tissue-based effector class control Gar Hildenbrand Dir Epidemiology - Gerson Research Organization Dir Research – Centro Hospitalario Internacional del Pacifico SA Lecture and PowerPoint presentation to the American Academy of Anti-Aging Medicine Fellowship in Integrative Cancer Therapy: Module II June 25, 2011 Las Vegas, Nevada Fellowship Dir: Mark Rosenberg, M.D. Abstract Gerson labored alone at first, and later with extraordinary support, to develop a nutritional immunotherapeutic approach to tuberculosis. This disciplined clinical investigation led to some unconventional ways of conceiving of and monitoring the immune response of tissues per se, and manipulating them through diet. Gerson translated this new approach into a method of cancer management. Matzinger’s Danger Model predicts that an improvement in tissue function will lead to Garmore Hildenbrand: effective effector class control. Lecture Gar Hildenbrand: What if the immune system is not a surveillance army of specialized lymphocytes with advanced knowledge of self and not-self? What if Charlie Janeway was wrong? What if the tissues, themselves, initiate, tailor, am- plify and signal the completion of immune responses? What if T-regulatory cells express helper functions according to instructions from the tissues? What if we’re misidentifying T-regulatory cells due to the culture media and the assays we are using in our experiments? What if we are missing the tissue responses that govern the class of effector? Christeene and I had dinner and too much wine a couple of months back with Polly Matzinger, who’s the Chief of the T- cell Tolerance Memory Section of the Immunology Lab at NIAID and a co-conspirator along with Steve Groft, the Direc- tor of the Office of Rare Diseases Research, to go back in on the Coley question, to start with large animals and live streptococcus pyogenes infections, because the large animals, like Arabian horses, can get melanomas, for example; dogs can get sarcomas, that are much, much closer than murine models to human beings. And really, if we want to know what makes tumors clear, we need to know what aspect of immunity is evoked. And of course, at this point, “what aspect of immunity” becomes a much larger question. Hildenbrand G pg. 4 I’m going to do what Dr. Pauling always did in his lectures, and he Students generally learn that the immune system told us that we should do this. I’m going to read what is up on the matches the effector class to the pathogen that it is fighting (for example, making IgE against worms, screen instead of say something else, which always drove him crazy and cytotoxic T lymphocytes (CTL) against viruses when a speaker would do that. and intracellular bacteria). But it is not easy to see how the immune system could discriminate Gerson labored alone at first — we’re talking about Max Gerson between worms, viruses or intracellular bacteria, as T cell receptors bind peptide-MHC complexes, B back in the 19-teens and twenties, in Germany, in Bielefeld — later cell receptors bind small epitopes on proteins, with extraordinary support, to develop a nutritional immunotherapeu- carbohydrates and lipids that are present in most tic approach to tuberculosis. This disciplined clinical investigation led living organisms; ... Slide 3 to some unconventional ways of conceiving of and monitoring the immune response of tissues per se, and manipulating them through Matzinger PC, Kamala T. Tissue-based class control: the other side of tolerance. Nature Reviews Immunology 2011;11:221-230 diet. Gerson translated this new approach into a method of cancer management — I could say via tuberculosis, which is where he started — Matzinger’s Danger Model predicts that an improvement (cont) and the ‘innate’ receptors, such as the Toll- in tissue function will lead to more effective effector class control. like receptors (TLRs) and NOD-like receptors (NLRs) are so promiscuous that they don’t Sounds interesting. distinguish between ligands from different phyla, or between pathogen-derived and self-derived signals From a February publication of Polly Matzinger, in the February is- ... So, what controls the effector class of an sue of Nature Reviews Immunology, this year, Students generally immune response? The idea that it might be the tissues, rather than the immune system, has grown learn that the immune system matches the effector class to the slowly over the 13 years that we have been pathogen — matches the effector class to the pathogen — that it is studying immunity from the perspective of the fighting (for example, making IgE against worms, and cytotoxic T danger model. Slide 4 lymphocytes (CTL) against viruses and intracellular bacteria). But it is not easy to see how the immune system could discriminate be- Matzinger PC, Kamala T. Tissue-based class control: the other side of tolerance. Nature Reviews Immunology 2011;11:221-230 tween worms, viruses or intracellular bacteria, as T cell receptors bind peptide-MHC complexes, B cell receptors bind small epitopes on proteins, carbohydrates and lipids that are present in most living (cont) Initially, the model did not offer any clues as organisms; and the ‘innate’ receptors, such as the Toll-like receptors to how one effector class might be chosen over another, as it was designed to cover only the (TLRs) and NOD-like receptors (NLRs) are so promiscuous that they immune system’s first decision (whether to respond don’t distinguish between ligands from different phyla, or between or not). It proposed that perturbed tissues initiate pathogen-derived and self-derived signals ... So, what controls the immune responses by sending alarm signals that activate local antigen-presenting cells (APCs), effector class of an immune response? The idea that it might be the whereas healthy tissues display their own antigens tissues, rather than the immune system, has grown slowly over the or allow ‘resting’ APCs to display those antigens to 13 years that we have been studying immunity from the perspective induce peripheral tolerance... of the danger model. Slide 5 Continuing ... Initially, the model did not offer any clues as to how Matzinger PC, Kamala T. Tissue-based class control: the other side of tolerance. Nature Reviews Immunology 2011;11:221-230 one effector class might be chosen over another, as it was designed to cover only the immune system’s first decision (whether to respond or not). It proposed that perturbed tissues initiate immune responses (cont) In effect, this model suggested that turning by sending alarm signals that activate local antigen-presenting cells immune responses on or off was the prerogative of (APCs), whereas healthy tissues display their own antigens or allow the tissues. It takes only a small step to suggest that tissues may also control the effector class, ‘resting’ APCs to display those antigens to induce peripheral toler- such that the class of an immune response is ance. In effect, this model suggested that turning immune responses tailored to the tissue in which it occurs, rather than on or off was the prerogative of the tissues. It takes only a small step to the invading pathogen. to suggest that tissues may also control the effector class, such that the class of an immune response is tailored to the tissue in which it occurs, rather than to the invading pathogen. Slide 6 Just think about it, if you had a T-cell response in your gut, or your Matzinger PC, Kamala T. Tissue-based class control: the other side of tolerance. Nature Reviews Immunology 2011;11:221-230 brain, or your eye, you would lose those structures and organs, be- Hildenbrand G pg. 5 cause it is such a destructive response. So an Ig response is re- quired in those tissues. How in the world could the immune system In fact, we should perhaps redefine the immune know to respond that way? system to include every tissue in the body. Again with Polly ... In fact, we should perhaps redefine the immune system to include every tissue in the body. Slide 7 This is “girlfriend,” here. Polly is 73 years old. She started out as a cocktail waitress in the Playboy Lounge where some scientists were Matzinger PC, Kamala T. Tissue-based class control: the other side of tolerance. Nature Reviews talking and she overheard them. They were talking about Immunology 2011;11:221-230 biomimicry and she asked, as she was serving the cock- tails, “Why doesn’t anything mimic a skunk?” To which, to Slide 8 her delight, the scientists responded by engaging her in a Polly Matzinger (and disciple) conversation and, over a period of time, one of them be- came convinced that she had a gift and talked her into pursuing studies in the sciences. And as I said, she is now the long-term head of the Ghost Lab, so-called be- cause for the first nine months there was no one there, because Polly had gotten it into her head that string the- ory might be important.
Recommended publications
  • Cancer Forum
    Cancer Forum November 2005 Volume 29 Number 3 ISSN 0311-306X List of Contents Forum: Innovations in cancer imaging Overview Lourens Bester 139 Vascular access devices and the oncology patient Stuart Lyon 140 Magnetic resonance and oncology imaging Rathan Subramanian and Murali Guduguntla 144 Implantable peritoneal ports in the management of malignant ascites – technical innovation Lourens Bester 147 Vertebroplasty in oncology: a novel approach to pain relief in the cancer patient Glen Schlaphoff 148 Articles Medical Oncology Group of Australia, Pierre Fabre Cancer Achievement Award: Snake oil, coffee enemas and other famous nostrums for cancer – a recent history of cancer quackery in Australia Ray Lowenthal 150 The Cancer Council Australia’s Student Essay Competition: Cancer education for medical students: opportunities and challenges for the 21st Century Jennifer Anderson 154 Reports Australian behavioural research in cancer 158 Cancer Trials Database Victoria – first of its type in Australia 162 Cancer Institute NSW Standard Cancer Treatments (CI-SCaT) 163 News and announcements 165 Book reviews 168 Calendar of meetings 176 F ORUM Innovations in cancer imaging Overview Lourens Bester extensive list of references in his bibliography. Westmead Private Hospital & Westmead Public Hospital, The management of pain, once entirely the domain of a Sydney pain or anaesthetic specialist has also become part of the Email: [email protected] daily workload of the interventional radiologist. Clearly, the interventional radiologist is now a member of the multi- disciplinary oncological team. Glen Schlaphoff describes The burgeoning development of new computer applications ‘cementoplasty’ which is a procedure used for treating and increased funding from venture capitalists has lead bone pain in patients with metastatic bone disease.
    [Show full text]
  • The Importance of a Histological Diagnosis When Diagnosing and Treating Advanced Cancer. Famous Patient Recovery
    Haines and Lowenthal 1 Hypothesis. The importance of a histological diagnosis when diagnosing and treating advanced cancer.* Famous patient recovery may not have been from metastatic disease. Ian E Haines Ray M Lowenthal Correspondence: Dr Ian E Haines Melbourne Oncology Group Suite 45 Cabrini Medical Centre, Malvern 3144 Australia Ph: 03-9509-3744 Email: <[email protected]> This is an Accepted Article that has been peer-reviewed and approved for publication in the Internal Medicine Journal, but has yet to undergo copy- editing and proof correction. Please cite this article as an “Accepted Article”; doi: 10.1111/j.1445-5994.2011.02686.x Haines and Lowenthal 2 Over the last 33 years, mystery has surrounded the diagnosis and treatment of a very influential Australian patient. In the long gap between amputation of his leg for osteogenic sarcoma and successful treatment for widespread tuberculosis, he was told he had advanced and incurable metastatic sarcoma. Details of his recovery and the treatments used have been extensively described. An alternative hypothesis is advanced to explain his recovery. This hypothesis is advanced for two reasons. The first is to underline the modern recognition of the need to consider diagnostic investigations, including biopsy, before assigning the diagnosis of advanced cancer to any patient. This principle is especially vital in cases where two diseases can present in the same way. The second is that there a risk that if diseases are incorrectly labelled, incorrect treatments may be given. This can lead to misleading interpretations being made about non- traditional treatments providing “cures,” which can influence the decision-making of patients seeking answers and even lead them away from potentially curative traditional treatments.
    [Show full text]
  • Evaluation of the Effects of a Psychosocial Intervention on Mood, Coping and Quality of Life in Cancer Patients
    Evaluation of the effects of a psychosocial intervention on mood, coping and quality of life in cancer patients Nicola Reavley BSc (Hons) Pharmacology Bristol University, UK Submitted in fulfilment of the requirements for the Doctor of Philosophy, Faculty of Life and Social Sciences, Swinburne University of Technology 2006 Acknowledgements Many people have provided me with very valuable assistance, guidance and support during the time taken to do this research. I wish to thank my supervisors, particularly Professor Avni Sali, without whom I would not have started and Dr Julie Pallant without whom I would not have finished. Professor Sali’s vision, encouragement and positive attitude have been an inspiration, and Dr Pallant’s support, clarity and attention to detail have been invaluable. My thanks go to Dr Ian Gawler and Dr Ruth Gawler for generously giving of their time and guidance to enable me to research the work they do. I would also like to thank the staff at The Gawler Foundation, Professor John Patterson, Dr Craig Hassed, Dr Luis Vitetta and Pauline McKinnon. And last but not least, I owe my thanks to the people that gave up their time to complete the questionnaires. Many of these were cancer patients and their courage and positive attitude in the face of difficult circumstances were unfailingly inspiring. Declaration This thesis contains no material which has been accepted for the award of any other degree or diploma in any University of other institution. To the best of my knowledge this thesis contains no material previously published or written by another person except where due reference is made in the text of the thesis.
    [Show full text]
  • Imj Haines and Lowenthal
    Internal Medicine Journal 42 (2012) PERSONAL VIEWPOINT Hypothesis. The importance of a histological diagnosis when diagnosing and treating advanced cancer. Famous patient recovery may not have been from metastatic diseaseimj_2686 212..216 I. E. Haines1,2 and R. M. Lowenthal3 1Medical Oncology, Cabrini Health, and 2Monash University Department of Medicine, Alfred Hospital, Melbourne, Victoria, and 3Department of Haematology/Oncology, Royal Hobart Hospital, Hobart, Tasmania, Australia Key words Abstract advanced and metastatic cancer, osteogenic sarcoma, accurate histological diagnosis, Over the past 33 years, mystery has surrounded the diagnosis and treatment of a very tuberculosis, choosing appropriate treatment. influential Australian patient. In the long gap between amputation of his leg for osteo- genic sarcoma and successful treatment for widespread tuberculosis, he was told he had Correspondence advanced and incurable metastatic sarcoma. Details of his recovery and the treatments Ian E. Haines, Melbourne Oncology Group, used have been extensively described. An alternative hypothesis is advanced to explain Cabrini Medical Centre, Suite 45, 183 his recovery. This hypothesis is advanced for two reasons. The first is to underline the Wattletree Rd., Malvern, Melbourne, Vic. 3144, modern recognition of the need to consider diagnostic investigations, including biopsy, Australia. before assigning the diagnosis of advanced cancer to any patient. This principle is E-mail: [email protected] especially vital in cases where two diseases can present in the same way. The second is that there a risk that if diseases are incorrectly labelled, incorrect treatments may be Received 27 April 2011; accepted 18 October given. This can lead to misleading interpretations being made about non-traditional 2011.
    [Show full text]
  • Low Dose Naltrexone (LDN) Why Weren't You Told?
    Those Who Suffer Much Know Much about Low Dose Naltrexone (LDN) Why weren’t you told? aann oolldd ddrruugg aa ccoonnttrroovveerrssiiaall ttrreeaattmmeenntt bbeenneeffiittiinngg iimmmmuunnee ssyysstteemm ddiisseeaasseess tthhoouussaannddss aacchhiieevviinngg hheeaalltthh ssuucccceessss hhuunnddrreeddss ooff rreeccoorrddeedd ppaattiieenntt tteessttiimmoonniieess WWHHYY hhaavveenn’’tt yyoouu hheeaarrdd ooff iitt?? WWHHYY wwoonn’’tt yyoouu bbee ooffffeerreedd iitt?? In keeping with the altruism of contributors Case Health continues to offer this book to you FREE without charge or expectation You can 'share it forward' or host it on a website under the same philosophy without modification and free of charge in this fifth revision 51 Health Case Studies 19 health professional interviews & perspectives low dose naltrexone (LDN) in the beneficial treatment of immune system diseases Supporting evidence for the value of patient testimony to e-health systems worldwide Cris Kerr, Case Health 55 Webb Street, Brisbane, Queensland, Australia 4053 Advocating the value of patient testimony since May 2001 © Case Health 2006, revised July 2007, July 2008, July 2009, July 2010 (Original Websites: casehealth.com.au & casehealth.com May 2001 to May 2009) The case studies in this book feature Low Dose Naltrexone (LDN) an old drug a controversial treatment benefiting immune system diseases thousands achieving health success hundreds of recorded patient testimonies WHY haven’t you heard of it? WHY won’t you be offered it? of those conditions LDN has benefited the following are featured in this book Multiple Sclerosis HIV Hepatitis B & C Primary Lateral Sclerosis Cancer, Lymphoedema Fibromyalgia Crohn’s Disease Arthritis Parkinson’s Disease Relapsing Polychondritis (RPC) and diseases of immune system dysfunction Supporting data for this book has been assembled from untested patient testimony of health success.
    [Show full text]
  • Hypothesis. the Importance of a Histological Diagnosis When Diagnosing and Treating Advanced Cancer. Famous Patient Recovery
    Internal Medicine Journal 42 (2012) PERSONAL VIEWPOINT Hypothesis. The importance of a histological diagnosis when diagnosing and treating advanced cancer. Famous patient recovery may not have been from metastatic diseaseimj_2686 212..216 I. E. Haines1,2 and R. M. Lowenthal3 1Medical Oncology, Cabrini Health, and 2Monash University Department of Medicine, Alfred Hospital, Melbourne, Victoria, and 3Department of Haematology/Oncology, Royal Hobart Hospital, Hobart, Tasmania, Australia Key words Abstract advanced and metastatic cancer, osteogenic sarcoma, accurate histological diagnosis, Over the past 33 years, mystery has surrounded the diagnosis and treatment of a very tuberculosis, choosing appropriate treatment. influential Australian patient. In the long gap between amputation of his leg for osteo- genic sarcoma and successful treatment for widespread tuberculosis, he was told he had Correspondence advanced and incurable metastatic sarcoma. Details of his recovery and the treatments Ian E. Haines, Melbourne Oncology Group, used have been extensively described. An alternative hypothesis is advanced to explain Cabrini Medical Centre, Suite 45, 183 his recovery. This hypothesis is advanced for two reasons. The first is to underline the Wattletree Rd., Malvern, Melbourne, Vic. 3144, modern recognition of the need to consider diagnostic investigations, including biopsy, Australia. before assigning the diagnosis of advanced cancer to any patient. This principle is E-mail: [email protected] especially vital in cases where two diseases can present in the same way. The second is that there a risk that if diseases are incorrectly labelled, incorrect treatments may be Received 27 April 2011; accepted 18 October given. This can lead to misleading interpretations being made about non-traditional 2011.
    [Show full text]
  • The Medical Journal of Australia
    LETTERS Cancer patients at risk from correct sequence of events and relevant and meditation. Although diet and medita- inaccurate clinical reporting in inclusions, are outlined in Box 1. In sum- tion may be adjuncts to a patient’s well- a high-profile alternative mary, the major errors in the article were as being, it is unlikely in this case that they follows: were curative, and certainly veganism was treatment story: comments • Timeline errors. The authors stated that not a relevant factor. Immunotherapy with and corrections the patient first saw Dr Meares in Septem- BCG vaccine treatments, the timing of Grace O Gawler ber 1976, after chemotherapy had failed. In symptoms and the patient’s eventual diag- fact, the patient consulted Meares as a first- nosis of tuberculosis could be associated TO THE EDITOR: I would like to correct line treatment approach on 12 December with his remission, as postulated by his some inaccuracies in an article by Jelinek 1975, and did not consider chemothera- radiation oncologist in 1978.6 There is and Gawler in the December 2008 issue of peutic options until September 1976. The extensive scientific literature about remis- the TheJournal Medical about Journal a survivor of Australia of dissemi- ISSN: authors also stated that the patient had sion of cancer, including osteosarcoma, nated0025-729X osteosarcoma. 20 September1 2010 193 6 palliative radiotherapy in September 1976. associated with febrile conditions.5,8-15 The668-669 article describes a 58-year-old man In fact, the patient had only one course of The patient’s sporadic visits to doctors ©The Medical Journal of Australia who2010 was www.mja.com.audiagnosed in 1974, at the age of palliative radiotherapy treatment, in Febru- meant that metastases were not diagnosed 24 Lettersyears, with histologically confirmed ary 1976.
    [Show full text]
  • The Medical Journal of Australia
    LETTERS Cancer patients at risk from correct sequence of events and relevant and meditation. Although diet and medita- inaccurate clinical reporting in inclusions, are outlined in Box 1. In sum- tion may be adjuncts to a patient’s well- mary, the major errors in the article were as being, it is unlikely in this case that they a high-profile alternative follows: were curative, and certainly veganism was treatment story: comments • Timeline errors. The authors stated that not a relevant factor. Immunotherapy with and corrections the patient first saw Dr Meares in Septem- BCG vaccine treatments, the timing of Grace O Gawler ber 1976, after chemotherapy had failed. In symptoms and the patient’s eventual diag- fact, the patient consulted Meares as a first- nosis of tuberculosis could be associated TO THE EDITOR: I would like to correct line treatment approach on 12 December with his remission, as postulated by his some inaccuracies in an article by Jelinek 1975, and did not consider chemothera- radiation oncologist in 1978.6 There is and Gawler in the December 2008 issue of peutic options until September 1976. The extensive scientific literature about remis- the TheJournal Medical about Journal a survivor of Australia of dissemi- ISSN: authors also stated that the patient had sion of cancer, including osteosarcoma, nated0025-729X osteosarcoma. 20 September1 2010 193 6 palliative radiotherapy in September 1976. associated with febrile conditions.5,8-15 The668-669 article describes a 58-year-old man In fact, the patient had only one course of The patient’s sporadic visits to doctors ©The Medical Journal of Australia who2010 was www.mja.com.audiagnosed in 1974, at the age of palliative radiotherapy treatment, in Febru- meant that metastases were not diagnosed 24 Lettersyears, with histologically confirmed ary 1976.
    [Show full text]